Borderline tuberculoid leprosy mimicking sarcoidosis
A case report

Jian Liu, MD¹⁻²⁻*, Yan Wen, MD¹⁻²⁻, Yan Xing, MD¹⁻²⁻, Shuo Wang, MD²

Abstract
Introduction: Leprosy is a chronic infectious granulomas disease caused by Mycobacterium leprae that can manifest as a wide variety of immunological and clinical features.

Case summary: Here, we describe the case of a woman with clinical characteristics of borderline tuberculoid (BT) leprosy that manifested as 3 asymmetric skin lesions involving her hip and lower limbs. This unusual presentation was initially misdiagnosed as sarcoidosis because noncaseating granulomas are a histopathological feature of both diseases. Differentiation and the diagnosis of BT leprosy was achieved using real-time polymerase chain reaction (PCR) to amplify an M leprae specific DNA sequence and to detect serum antibodies specific to M leprae antigens. Accordingly, a 6-month course of multidrug therapy led to a marked improvement in the skin lesions.

Conclusion: The use of auxiliary tests including real-time PCR to amplify an M leprae-specific DNA sequence, enzyme-linked immunosorbent assay, and dipstick detection of serum antibodies specific to M leprae antigens are good methods to obtain a correct diagnosis of BT leprosy.

Abbreviations: BB = mid-borderline, BI = bacteria index, BL = borderline lepromatous, BT = borderline tuberculoid, BTMRI = Beijing Tropical Medicine Research Institute, CT = computed tomography, LD = leprosy (DI) diagnostic, LL = lepromatous leprosy, M leprae = Mycobacterium leprae, MB = multibacillary, MDT = multidrug therapy, PB = paucibacillary, PCR = polymerase chain reaction, PGL-I = phenolic glycolipid-I, SSS = skin slit smear, TT = tuberculoid leprosy, WHO = World Health Organization.

Keywords: diagnosis, granulomatous disease, leprosy, sarcoidosis

1. Introduction

Leprosy or Hansen disease is a chronic granulomatous disease caused by the intracellular bacterium Mycobacterium leprae that invades skin and peripheral nerves.[1] The disease is distributed throughout the world, mainly in Brazil, India, Southeast Asia, and Africa. Leprosy can manifest as a wide spectrum of clinical features, but the predominant manifestations are skin lesions with diminished sensation, thickened subcutaneous nerves, and the presence of acid fast bacilli. The Ridley-Jopling classification criteria,[2] histopathologic findings, skin-slit smear (SSS) with acid-fast staining, and bacteria index (BI) categorize the disease into 5 types (tuberculoid leprosy [TT], borderline tuberculoid [BT], mid-borderline [BB], borderline lepromatous [BL], and lepromatous leprosy [LL]). In polar TT cases, skin patch lesions manifest as slightly hypochromic, round macules with discontinuously populate, well-bordered, lesions insensitive to touch, and a low BI. The extreme LL form is characterized by a symmetrical distribution, diffuse infiltration, nodules, and madarosis, with a higher number of infiltrated skin lesions and high BI compared with the other types. Borderline leprosy is characterized by the appearance of multiple irregular, thick granular margins and small satellite, coalescent lesions, with usually positive bacilloscopy results. Patients with paucibacillary (PB) leprosy (TT and BT) are treated for 6 months with a regimen consisting of rifampicin and dapsone. Given their increased bacteria load, patients with multibacillary (MB) leprosy (BB, BL, and LL) receive treatment for 12 months with clofazimine in addition to rifampicin and dapsone.

Based on the M leprae-specific cell-mediated immunity of the host, the types of leprosy from strongest to weakest responses are as follows: TT, BT, BB, BL, and LL.[3] To guide treatment decisions, the World Health Organization (WHO) classified leprosy into the operational classifications of PB and MB leprosy according to the number of skin lesions and involved nerves.[1] In terms of histopathologic findings, PB (TT and BT) is characterized by epithelioid granuloma cells, whereas MB (BB, BL, and LL) is characterized by maculat granuloma cells.[1] Leprosy is currently diagnosed by a physical examination, and when possible, a microbiological evaluation using SSS.[4,3]

Here, we describe a case of BT leprosy that was originally mistaken for sarcoidosis. We discuss the clinical and histologic characteristics of the disease and the methods used to obtain the correct diagnosis.
2. Case report

Informed consent was obtained from the individual participant in the study.

A 40-year-old woman who worked as a peasant farmer in Shandong province, 300 miles from Beijing, China, was referred to a dermatology clinic within that province because she had 3 patchy rashes (Fig. 1A–C). One year earlier, she had 3 large patchy rashes—1 on the hip and 2 on her lower limbs. The patch on the hip was wide, raised, and erythematous with well-defined margins sloping toward the center of the lesion. The erythematous patch on the dorsum of her foot had sharp edges with thick granular margins and small satellite lesions. A skin biopsy was performed and revealed a noncaseating epitheloid granuloma (Fig. 2A). On the basis of this observation, we diagnosed the patient as having cutaneous sarcoidosis. She was prescribed some herbal medicine for 1 month, after which she felt aggravated and visited the hospital again. Then a skin biopsy from the patch on her right leg was obtained. Similar to the previous biopsy, the result showed numerous noncaseating epithelioid granuloma cells consisting of histiocytes and giant cells surrounded by lymphocytes infiltrating the adnexa structures (Fig. 2B, C). Results of the Ziehl-Neelsen staining and polymerase chain reaction (PCR) test for *Mycobacterium tuberculosis* were negative, and routine laboratory screening test results for the hemoglobin level, leukocyte count, and liver and renal parameters were all within normal range. Because of the possibility of sarcoidosis, plasma dipeptidyltransferase and calcium levels were measured, and chest radiography was performed. All these test results were also normal. Consequently, leprosy was suspected, and the patient was referred to Beijing Tropical Medicine Research Institute (BTMRI) for a formal assessment.

By the time of referral to BTMRI, the 3 patches became asymmetrically distributed on the patient’s hip and lower limbs, while no patches were founded on her trunk or scalp. All the patches were not sensitive to light touch, and the patient was unable to discriminate between hot and cold temperatures in these areas. The eye examination was normal, and there was no enlargement of the nervus auricularis magnus. Subsequently, SSS with acid-fast staining was performed at 5 different sites: both earlobes, both eyebrows, and the chin. Results of the microscopic evaluation were negative. Therefore, *M leprae*-specific real-time PCR and enzyme-linked immunosorbent assay were also performed to detect serum antibodies against phenolic glycolipid (PGL)-I and leprosy IDRI diagnostic (LID)-1. The results of real-time PCR for an *M leprae*-specific target was positive, whereas the antibody responses against LID-1 and PGL-I mimetic NDO-BSA were positive but weak (OD >0.05) (Table 1). On the basis of the patient’s clinical presentation and results of the assays, we diagnosed the patient as having BT leprosy. Accordingly, we prescribed her with dapsone (100 mg daily) and rifampicin (600

---

**Figure 1.** Macroscopic presentation of the plaques. (A) Palm-sized plaques are shown on the right hip. These plaques lacked a clear edge, and the fringes were raised higher than the skin. Normal skin is occasionally observed among the patches. (B) On the right leg, palm-sized plaques are present with varying shades of color, deep and shallow edges, and satellite foci. (C) On the inside of the right foot, the plaque has dark coloring, undefined edges, and satellite foci.

**Figure 2.** Microscopic observations of the skin biopsies. (A) Under 100× magnification, thinning of the skin is not clearly seen, infiltration is not obvious, and shallow blood vessels are visible around the granulomatous adnexal tissue in the mid-dermis. (B) Under 400× magnification, granulomatous changes are visible, with epithelioid cells and lymphocyte infiltration. (C) Under 400× magnification, sections show a negative result with acid-fast staining.
mg monthly) for 6 months in accordance with the WHO recommendation for treating PB leprosy.

The skin lesion was markedly improved by completion of the 6-month multidrug therapy (MDT) (Figs. 3 and 4A, B), providing a retrospective conformation of the diagnosis of BT leprosy.

3. Discussion

Sarcoidosis is a multisystem noncaseating granulomatous disease that affects organs, such as the lungs, skin, lymph nodes, eyes, and liver. The etiology of sarcoidosis is unknown at present, and although some cases are self-limiting, the prognosis is usually good with corticosteroids. Similar to leprosy, the most common histopathological feature of sarcoidosis is a kind of epithelioid cell granulomas. Some cases of PB leprosy may be confounded with sarcoidosis.[6]

Auxiliary tests are now becoming available to assist in the diagnosis of leprosy. Examination of the sera is useful for detecting antibodies against LID-1 and LID-NDO with high sensitivity and specificity to aid in the diagnosis of leprosy and help in identifying people with asymptomatic *M. leprae* infection before lesion development. We found LID-1 to be an important parameter in the detection of new cases of leprosy, even in detecting a proportion of patients with PB leprosy. PCRs-based tests can improve sensitivity of the PB diagnosis. Real-time PCR detection of *M. leprae* in DNA could be superior to nested-PCR assay, which is prone to contamination with PCR products in the second round of amplification, and real-time PCR can be used as a rapid, sensitive, and specific confirmatory test to identify the presence of *M. leprae* in tissue specimens for diagnosing PB leprosy.[8–10]

The patient with BT leprosy described herein seldom had the clinical characteristics of sarcoidosis, such as hypercalcaemia, a high globulin level, hematocrit disease, a low lymphocyte count, leukemia, rapidly increased blood sedimentation level, circulating immune complex deposition, but she did have some clinical symptoms of sarcoidosis, including skin numbness, pain/warm touch sensory disorder, and numb areas near the skin lesion. Therefore, she was diagnosed as having sarcoidosis at her local clinic in the Shandong province. After a period of ineffective treatment and flaring of the lesions, the patient was referred to BTMRI under the suspicion of leprosy. The clinical examination was conducted by our experienced clinicians and additional diagnostic assays were performed. Although the microbiology of SSS and histopathologic results were negative, antibodies against both LID-1 and PGL-1 (ND-BSA) were detected at low levels, and real-time PCR amplifying an *M. leprae* gene fragment was positive. A diagnosis of BT leprosy was made, and after providing MDT for 6 months, the skin lesions showed marked improvement.

| Table 1  | Results of the laboratory assays. |
|----------|----------------------------------|
| Number   | Type | BI (SSS) | Real time PCR | ELISA |
| C1       | BT   | 0        | 28.898        | 1.36 × 10^3 | 0.093 | 0.142 |

BI = Bacteria Index, BT = borderline tuberculoid, LID = leprosy IDRI diagnostic, PCR = polymerase chain reaction, SSS = skin slit smear.
Acknowledgment

The authors express gratitude to Senior Scientist Malcolm Duthie, Ph.D. for editing and revising this manuscript.

Author contributions

Formal analysis: Yan Wen.
Project administration: Jian Liu.
Supervision: Yan Xing.
Writing – original draft: Jian Liu.
Writing – review and editing: Shuo Wang.

References

[1] Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev 2006;19:338–81.
[2] Paula Vaz Cardoso L, Dias RF, Freitas AA, et al. Development of a quantitative rapid diagnostic test for multibacillary leprosy using smart phone technology. BMC Infect Dis 2013;13:497.
[3] Pardillo FE, Fajardo TT, Abalos RM, et al. Methods for the classification of leprosy for treatment purposes. Clin Infect Dis 2007;44:1096–9.
[4] Nicholls PG, Croft RP, Richards JH, et al. Delay in presentation, an indicator for nerve function status at registration and for treatment outcome—the experience of the Bangladesh Acute Nerve Damage Study cohort. Lepr Rev 2003;74:449–56.
[5] Nicholls PG, Ross L, Smith WC. Promoting early detection in leprosy—a literature review to identify proven and potential interventions addressing patient-related delay. Lepr Rev 2006;77:298–310.
[6] Bonfili AA, Orefice F. Sarcoidosis. Semin Ophthalmol 2005;20:177–82.
[7] Duthie MS, Balagon MF, Maghanoy A, et al. Rapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosy. J Clin Microbiol 2014;52:613–9.
[8] Martinez AN, Ribeiro-Alves M, Sarno EN, et al. Evaluation of qPCR-based assays for leprosy diagnosis directly in clinical specimens. PLoS Negl Trop Dis 2011;5:e1354.
[9] Kramme S, Bretzel G, Panning M, et al. Detection and quantification of Mycobacterium leprae in tissue samples by real-time PCR. Med Microbiol Immunol 2004;193:189–93.
[10] Yan W, Xing Y, Yuan LC, et al. Application of RLEP real-time PCR for detection of M. leprae DNA in paraffin-embedded skin biopsy specimens for diagnosis of paucibacillary leprosy. Am J Trop Med Hyg 2014;90:524–9.